162 related articles for article (PubMed ID: 36566690)
1. "This house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients".
Galimberti V; Ribeiro Fontana SK; Vicini E; Morigi C; Sargenti M; Corso G; Magnoni F; Intra M; Veronesi P
Breast; 2023 Feb; 67():21-25. PubMed ID: 36566690
[TBL] [Abstract][Full Text] [Related]
2. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment.
Galimberti V; Ribeiro Fontana SK; Maisonneuve P; Steccanella F; Vento AR; Intra M; Naninato P; Caldarella P; Iorfida M; Colleoni M; Viale G; Grana CM; Rotmensz N; Luini A
Eur J Surg Oncol; 2016 Mar; 42(3):361-8. PubMed ID: 26746091
[TBL] [Abstract][Full Text] [Related]
3. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up.
Kahler-Ribeiro-Fontana S; Pagan E; Magnoni F; Vicini E; Morigi C; Corso G; Intra M; Canegallo F; Ratini S; Leonardi MC; La Rocca E; Bagnardi V; Montagna E; Colleoni M; Viale G; Bottiglieri L; Grana CM; Biasuz JV; Veronesi P; Galimberti V
Eur J Surg Oncol; 2021 Apr; 47(4):804-812. PubMed ID: 33092968
[TBL] [Abstract][Full Text] [Related]
4. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.
Wu SY; Li JW; Wang YJ; Jin KR; Yang BL; Li JJ; Yu XL; Mo M; Hu N; Shao ZM; Liu GY
Int J Surg; 2023 Jul; 109(7):1863-1870. PubMed ID: 37132193
[TBL] [Abstract][Full Text] [Related]
5. Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer.
Liu Y; Wang Y; Feng S; Xu Z; Yao M; Huang X; Li P; Wu L; Liu C; Chen X; Liang C; Liu Z
Breast Cancer Res Treat; 2023 Feb; 197(3):515-523. PubMed ID: 36513955
[TBL] [Abstract][Full Text] [Related]
6. Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients.
Pinto CS; Peleteiro B; Pinto CA; Osório F; Costa S; Magalhães A; Mora H; Amaral J; Gonçalves D; Fougo JL
Breast Cancer; 2022 Jul; 29(4):709-719. PubMed ID: 35304711
[TBL] [Abstract][Full Text] [Related]
7. Axillary ultrasonography combined with pre-operative wire localisation of clipped node in nodal restaging after neoadjuvant chemotherapy in node positive breast cancer patients: a pilot study.
Pulappadi VP; Paul S; Hari S; Dhamija E; Manchanda S; Kataria K; Mathur S; Mani K; Gogia A; Deo S
Br J Radiol; 2021 Nov; 94(1127):20210788. PubMed ID: 34491822
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment.
Siso C; Esgueva A; Rivero J; Morales C; Miranda I; Peg V; Gil-Moreno A; Espinosa-Bravo M; Rubio IT
Eur J Surg Oncol; 2023 Oct; 49(10):106938. PubMed ID: 37244843
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic contribution of magnetic resonance imaging in the detection of axillary metastasis after neoadjuvant chemotherapy.
İriağaç Y; Karaboyun K; Çavdar E; Avci O; Kurtoğlu Özçağlayan Tİ; Öznur M; Ozkan Gurdal S; Şeber ES
Neoplasma; 2022 May; 69(3):741-746. PubMed ID: 35471979
[TBL] [Abstract][Full Text] [Related]
10. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
Caudle AS; Yang WT; Krishnamurthy S; Mittendorf EA; Black DM; Gilcrease MZ; Bedrosian I; Hobbs BP; DeSnyder SM; Hwang RF; Adrada BE; Shaitelman SF; Chavez-MacGregor M; Smith BD; Candelaria RP; Babiera GV; Dogan BE; Santiago L; Hunt KK; Kuerer HM
J Clin Oncol; 2016 Apr; 34(10):1072-8. PubMed ID: 26811528
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101636. PubMed ID: 34303211
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer.
Aragón-Sánchez S; Ciruelos-Gil E; López-Marín L; Galindo A; Tabuenca-Mateos MJ; Jiménez-Arranz S; Colmenero-Hernández M; Oliver-Pérez MR
Surg Oncol; 2022 Sep; 44():101823. PubMed ID: 36041377
[TBL] [Abstract][Full Text] [Related]
13. Our house believes that: The clipped lymph node is the true sentinel node after neoadjuvant chemotherapy in N+ patients.
Acea-Nebril B; García-Novoa A; Bouzón Alejandro A; Díaz Carballada C; Conde Iglesias C
Breast; 2023 Dec; 72():103592. PubMed ID: 37857128
[TBL] [Abstract][Full Text] [Related]
14. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
[TBL] [Abstract][Full Text] [Related]
15. Clipping a Positive Lymph Node Improves Accuracy of Nodal Staging After Neoadjuvant Chemotherapy for Breast Cancer Patients, but Does It Drive Management Changes?
Costarelli L; Arienzo F; Broglia L; La Pinta M; Scavina P; Meli EZ; Colavito MH; Ascarelli A; Campagna D; Mastropietro T; Manna E; Amato M; Andrulli AD; Schiavone A; Minelli M; Fortunato L
Ann Surg Oncol; 2024 May; 31(5):3186-3193. PubMed ID: 38427160
[TBL] [Abstract][Full Text] [Related]
16. False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy.
de Boniface J; Frisell J; Kühn T; Wiklander-Bråkenhielm I; Dembrower K; Nyman P; Zouzos A; Gerber B; Reimer T; Hartmann S
Breast Cancer Res Treat; 2022 Jun; 193(3):589-595. PubMed ID: 35451733
[TBL] [Abstract][Full Text] [Related]
17. Sentinel lymph node biopsy following neoadjuvant chemotherapy: an evidence-based review and recommendations for current practice.
Cavalcante FP; Millen EC; Novita GG; Zerwes FP; Mattar A; Machado RHS; Frasson AL
Chin Clin Oncol; 2023 Feb; 12(1):6. PubMed ID: 36922355
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of traditional targeted axillary dissection eligibility criteria for node-positive breast cancer after neoadjuvant chemotherapy in a prospective multicenter registry.
Loveland-Jones C; Gaughan J; Caudle A; Murphy B; Samiian L; Byrum S; Brill K; Germaine P; Zhang X; Yoon-Flannery K; Carter T; Lopez A; Gruner R; Fantazzio M; Kuerer H
Eur J Surg Oncol; 2024 Apr; 50(4):108245. PubMed ID: 38484493
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Axillary Lymph Node Marking with Magseed® before and after Neoadjuvant Systemic Therapy in Breast Cancer Patients: MAGNET Study.
Martínez M; Jiménez S; Guzmán F; Fernández M; Arizaga E; Sanz C
Breast J; 2022; 2022():6111907. PubMed ID: 35855102
[TBL] [Abstract][Full Text] [Related]
20. This house believes that: MARI/TAD is better than sentinel node biopsy after PST for cN+ patients.
van Hemert AKE; van Duijnhoven FH; Vrancken Peeters MTFD
Breast; 2023 Oct; 71():89-95. PubMed ID: 37562108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
